全球乳癌篩檢檢驗市場:產業分析與市場預測(2017年∼2022年)

乳癌篩檢檢驗，為了早期發現癌症而實施。美國癌症學會(American Cancer Society)發表，乳癌對女性來說是最常見的癌症，美國女性8人有1人一生中發生乳癌。還有美國的乳癌篩檢檢驗市場，預計今後10年將成長到10倍。

本報告提供全球乳癌篩檢檢驗市場相關調查，市場概要，各檢驗、地區的市場趨勢，市場規模的變化與預測，市場成長、阻礙因素以及市場機會分析，市場佔有率，競爭情形，主要企業的簡介等，全面性資訊。

目錄

第1章 簡介

• 報告概要
• 調查方法

第2章 乳癌篩檢檢驗市場概要

• 乳癌篩檢檢驗的法律規範
  • 歐洲
  • 美國
  • 其他國

第3章 市場動態

• 市場成長要素
  • 開發平台的乳癌篩檢檢驗的增加
  • 有效性高的篩檢檢驗的引進
  • 消費者的關注高漲
• 市場阻礙因素
  • 篩檢檢驗的成本
  • 償付制度
  • 不穩定經濟
• 市場機會
  • 新的檢驗法與開發方法
• 市場威脅
• 波特的五力分析
  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係

第4章 市場區隔

• 檢查別
  • 血液標記檢驗
  • 螢光原位雜合(FISH)檢驗
  • 免疫組織化學(IHC)檢驗
  • MammaPrint檢驗
  • 乳房X光攝影
  • 超音波檢驗
  • MRI檢驗
• 各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲
  • 南美

第5章 競爭情形

• 新產品的創新
• 協定，合作，聯盟，合資企業

第6章 企業簡介

• A&G Pharmaceutical, Inc.
• Abcodia Ltd.
• Agendia BV
• Armune BioScience, Inc.
• Biocrates Life Sciences AG
• BioMark Technologies Inc.
• Chronix Biomedical, Inc.
• Genomic Health, Inc.
• Myriad Genetics
• Insight Genetics, Inc.
• Metabolomic Technologies Inc.
• Nuclea Biotechnologies Inc.
• Siemens Healthcare Diagnostics Inc.
• Panacea Pharmaceuticals, Inc.
• Quest Diagnostics Incorporated
• Roche Diagnostics Limited
• HTC Molecular Diagnostics Inc.

第7章 附錄

• 簡稱
• 參考資料
• 參考文獻
• 免責聲明

Market Overview

The breast cancer screening test market is expected to register a CAGR of 4.5% over the forecast period. Factors that are responsible for the growth of this market include the increasing awareness about the early detection of breast cancer, the growing incidence of breast cancer, and the increasing government initiatives and support.

Early detection of breast cancer can lead to desired outcomes, including increased survival rate, number of treatment options, and improved quality of life. And the rising incidence of breast cancer is helping the market to grow in the forecast period. As per the Breastcancer.org, about one in eight US women (about 12.4%) will develop invasive breast cancer over the course of their lifetime. In 2018, an estimated 266,120 new cases of invasive breast cancer are anticipated to be diagnosed in women only in the United States, along with 63,960 new cases of non-invasive breast cancer. Since there is a rising need for the breast cancer screening test across developing as well as developed nations, the demand for breast cancer screening tests is increasing which is leading to the growth of this market.

Scope of the Report

Breast cancer screening is carried out to detect cancer in its early stages and ensure timely treatment to the patients. There are different types of breast cancer depending on the type of breast cell that becomes cancerous. Breast cancer can affect different parts of the breast, such as the ducts and the lobes.

Key Market Trends

Imaging Test is Expected to Dominate in the Breast Cancer Screening Test Segment

The most commonly used screening test for breast cancer is the imaging test and these imaging tests are considered as the most reliable ones. Mammograms are the most widely used tests to screen breast cancer. Since mammography is the gold standard technique used to screen breast cancer, governments and other healthcare organizations around the world are taking initiatives to provide women, between the ages of 50 and 75, access to mammography screening. This is increasing the global demand for mammography while laboratory and blood tests and other imaging tests are gaining popularity. Digital breast tomosynthesis can increase the diagnostic accuracy of mammography and is used for the assessment of equivocal or suspicious mammography findings. Other modalities, such as ultrasound and contrast-enhanced magnetic resonance imaging (MRI) play an important role in the diagnostics, staging, and follow-up of breast cancer.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for breast cancer screening test and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. This can be majorly attributed to the increasing incidence rates of breast cancer and rising awareness among the population for the early detection of cancer. The presence of the developed healthcare infrastructure is expected to propel the market in the United States.

Competitive Landscape

The breast cancer screening test market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. With the increasing awareness among the population and rising advances in the screening test, a few other smaller players are expected to enter the market and may come to hold a substantial share. Some of the major players of the market are Allengers, Biocrates Life Sciences AG, Myriad Genetics, Hologic Inc., and Siemens Healthineers, among others.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• Report customization as per the client's requirements
• 3 months of analyst support

Table of Contents

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Iincreasing Awareness about Early Detection of Breast Cancer
  • 4.2.2 Growing Incidence of Breast Cancer
  • 4.2.3 Increasing Government Initiatives and Support
• 4.3 Market Restraints
  • 4.3.1 Controversies Related to Mammography
  • 4.3.2 High Cost of Screening Tests in the Developing Countries
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Test
  • 5.1.1 Genomic Tests
    • 5.1.1.1 MammaPrint Test
    • 5.1.1.2 Breast Cancer Index Test
    • 5.1.1.3 Mammostrat Test
    • 5.1.1.4 PAM50 Test
    • 5.1.1.5 Oncotype DX Test
    • 5.1.1.6 Other Genomic Tests
  • 5.1.2 Imaging Test
    • 5.1.2.1 Mammograms
    • 5.1.2.2 Ultrasound
    • 5.1.2.3 MRI
    • 5.1.2.4 Tomography
    • 5.1.2.5 Other Imaging Tests
• 5.2 Geography
  • 5.2.1 North America
    • 5.2.1.1 US
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
  • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 UK
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
  • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
  • 5.2.4 Middle East & Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East & Africa
  • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Allengers Medical Systems Limited
  • 6.1.2 Myriad Genetics
  • 6.1.3 Agendia BV
  • 6.1.4 Armune BioScience Inc.
  • 6.1.5 Metabolomic Technologies Inc.
  • 6.1.6 Fujifilm Holdings Corporation
  • 6.1.7 Biocrates Life Sciences AG
  • 6.1.8 Siemens Healthineers
  • 6.1.9 Hologic Inc.
  • 6.1.10 Quest Diagnostics Incorporated

7 MARKET OPPORTUNITIES AND FUTURE TRENDS